COMP <GO>
CPIX vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Cumberland Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CPIX 2
— LLY 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LLY
LAST: $4.69 (+7.82%) • MKT CAP: $65.2M
dividend-safety
0.00%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CPIX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CPIX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.00% | 83.64% | +1.36 | CPIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.40% | 32.36% | -48.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 7.42% | 2.30% | +5.12 | CPIX | /fcf-yield <GO> |
| Operating Margin | -6.30% | 40.21% | -46.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | -6.40% | 31.90% | -38.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 45.51% | -27.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.72 | 9.29 | -8.57 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 66.6 | -31.35 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $65.2M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CPIX REV | LLY REV | CPIX GROSS % | LLY GROSS % | CPIX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | $65.18B | 85.0% | 83.0% | $4.8M | $16.81B |
| FY 2024 | $37.9M | $45.04B | 82.6% | 81.3% | -$678.6K | $8.82B |
| FY 2023 | $39.6M | $34.12B | — | 79.3% | $6.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CPIX // BETA —
LLY // BETA 0.51